Clinical Trial: A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07821658) titled 'A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease' on Sept. 09.

Brief Summary: The primary purpose of this study is to evaluate the safety of lecanemab-irmb in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 cm in participants treated with lecanemab-irmb.

The secondary purpose of this study is to:

Evaluate the safety of lecanemab-irmb in the real-world clinical setting as reported by events o...